General Practice and Primary Care Research Unit, University of Cambridge, Cambridge, UK.
Diabetologia. 2012 Jun;55(6):1651-9. doi: 10.1007/s00125-011-2441-9. Epub 2012 Jan 12.
There are continuing uncertainties about how much screening for type 2 diabetes brings forward the clinical diagnosis and the impact that earlier diagnosis has on health outcomes. We compared the duration of diabetes and health outcomes in a population invited for diabetes screening at 5-yearly intervals from 1990 (screened population) with those in a similar population not invited for screening (unscreened population).
This was a parallel-group, cohort study of people aged 40-65 years, free of known diabetes, identified from the population register of a general practice in Ely, Cambridgeshire, UK (n = 4,936). In 1990-1992, one-third (n = 1,705), selected randomly, received an invitation for screening for diabetes and cardiovascular risk factors at 5-yearly intervals (screened population). From the remainder of the sampling frame, 1,705 randomly selected individuals were invited to diabetes screening 10 years later (unscreened population). Patients with diabetes from both populations were invited for a health assessment, including biochemical, anthropometric and questionnaire measures, and testing for the presence of diabetic complications
Of the 199 eligible individuals with diabetes diagnosed during follow-up, 152 (76%) attended for health assessment. The median duration of clinically recognised diabetes was significantly longer in cases arising in the screened (5.0 years) compared with the unscreened population (1.7 years; p = 0.006). Clinical measures, prescribed medication and functional status were similar between screened and unscreened populations.
Diabetes screening resulted in cases being identified on average 3.3 years earlier, a difference significantly shorter than previous estimates. Earlier diagnosis did not appear to impact on health outcomes. Further evidence is needed to justify the introduction of population-based screening.
对于 2 型糖尿病筛查能够提前多久发现临床诊断以及早期诊断对健康结果的影响,目前仍存在诸多不确定性。本研究比较了每 5 年接受糖尿病筛查(筛查人群)和未接受筛查(未筛查人群)的人群中,糖尿病的持续时间和健康结果。
这是一项在英国剑桥郡伊利的一个普通实践人群登记处中,选择年龄在 40-65 岁之间、无已知糖尿病的人群(n=4936)进行的平行群组队列研究。1990-1992 年,三分之一(n=1705)随机选择的人群收到了每 5 年进行一次糖尿病和心血管风险因素筛查的邀请(筛查人群)。从剩余的抽样框架中,随机选择了 1705 名个体在 10 年后接受糖尿病筛查(未筛查人群)。来自两个人群的糖尿病患者均被邀请进行健康评估,包括生化、人体测量和问卷调查以及检测糖尿病并发症的存在。
在随访期间,199 名符合条件的糖尿病患者中有 152 名(76%)接受了健康评估。在筛查人群中,临床确诊的糖尿病的中位持续时间明显长于未筛查人群(5.0 年 vs. 1.7 年;p=0.006)。筛查人群和未筛查人群的临床指标、处方药物和功能状态相似。
糖尿病筛查使病例的平均发现时间提前了 3.3 年,这一差异明显短于之前的估计。早期诊断似乎并没有对健康结果产生影响。需要进一步的证据来证明人群筛查的引入是合理的。